Anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria

Effect of anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria - Effect of anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180092

Enrollment

Registered

2019-01-22

Start date

2018-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic prurigo and cholinergic urticaria

Interventions

treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who are resistant to the treatments such as topical administration of steroid and orally administration of anti-histamine drugs patients at age 20 or over out patients

Exclusion criteria

Exclusion criteria: patients orally administrated immune suppressants or high-dose steroid within three months. patients suffering from severe visceral diseases, autoimmune diseases, blood dosorders, and mental disorders patients who is pregnant or breast-feed patients judged inadequate to this study

Design outcomes

Primary

Measure	Time frame
skin symptom	—

Secondary

Measure	Time frame
itch, QOL, Blood examination	—

Contacts

Public ContactTsukasa Ugajin

Tokyo Medical and Dental University

ugajin.derm@tmd.ac.jp+81-3-5803-5286

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026